Last $0.14 USD
Change Today -0.007 / -4.93%
Volume 5.2K
As of 10:36 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

qrxpharma ltd-sponsored adr (QRXPY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $4.35
52 Week Low
08/28/14 - $0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

qrxpharma ltd-sponsored adr (QRXPY) Related Businessweek News

No Related Businessweek News Found

qrxpharma ltd-sponsored adr (QRXPY) Details

QRxPharma Limited, a specialty pharmaceutical company, develops and commercializes biopharmaceutical products primarily in Australia. The company’s pain management products include MOXDUO, which is an immediate-release oral capsule for the treatment of moderate to severe acute pain; Q8011, a controlled-release oral tablet that is a proprietary morphine/oxycodone formulation in Phase II clinical trials to provide analgesia in patients suffering from moderate to severe chronic pain; and Q8012, an intravenous dual opioid formulation of morphine and oxycodone, which has completed Phase II trial for acute moderate to severe hospital-based pain. It has a collaboration agreement with Aesica Formulation Development Limited for the promotion of its proprietary Stealth Beadlets abuse deterrence technology. QRxPharma Limited is based in North Sydney, Australia.

qrxpharma ltd-sponsored adr (QRXPY) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$337.3K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$219.7K
Senior Vice President of Global Business Deve...
Total Annual Compensation: A$286.9K
Compensation as of Fiscal Year 2013.

qrxpharma ltd-sponsored adr (QRXPY) Key Developments

QRxPharma Limited Announces Board Changes

QRxPharma Limited announced that Chairman, Dr. Peter Farrell and Director, Dr. Gary Pace have resigned from the QRxPharma board effective at 9:50 am (AEST) 9 July 2014 prior to commencement of the General Meeting (GM) requisitioned by shareholders associated with Langley Walker. It is expected that Bruce Hancox and Dr. Richard Treagus will be appointed as directors pursuant to resolutions in the requisitioned notice of meeting, with those appointments taking effect from the close of the meeting. The Company also announced that directors Peter Campbell and Michael Quinn have tendered their resignations from the QRxPharma board.

QRxPharma Limited, Special/Extraordinary Shareholders Meeting, Jul 09, 2014

QRxPharma Limited, Special/Extraordinary Shareholders Meeting, Jul 09, 2014.

QRxPharma Limited Announces Executive Changes

QRxPharma Limited announced that Dr. John Holaday has stepped down as Managing Director and Chief Executive Officer. The company's Board of Directors has appointed Dr. Edward Rudnic to Chief Executive Officer with immediate effect. Dr. Rudnic has been company's Chief Operating Officer since early 2012.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QRXPY:US $0.14 USD -0.007

QRXPY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QRXPY.
View Industry Companies

Industry Analysis


Industry Average

Valuation QRXPY Industry Range
No financial data is available for QRXPY.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QRXPHARMA LTD-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at